Accelerating Research in Genomic Oncology
The International Cancer Genome Consortium
2019-2030
www.icgc-argo.org
Background and Evolution

- ICGC ARGO is the new phase of the International Cancer Genome Consortium project, which comprehensively mapped the structural aberrations of cancer genomes and advanced our understanding of the molecular basis of cancer
  - ICGC 25k project ([www.icgc.org](http://www.icgc.org)) ~ 21,000 cancer genomes of primary cancers
  - ICGC Pan-Cancer Analysis of Whole Genomes- ~2,600 whole cancer genomes ([https://www.nature.com/collections/afdejfafdb/](https://www.nature.com/collections/afdejfafdb/))

- Hundreds of seminal works arising from ICGC data, and landmark articles appearing in the world’s elite scientific journals. No therapeutic is developed today without, in some way, applying the knowledge that ICGC has provided the world.

- In response to the realization of the potential of genomics in healthcare, in 2016 released a position “white paper” on the evolution of ICGC moving directly to impacting on human health
Vision: The ARGO project is the new phase of the ICGC; translating genomic knowledge to improve outcomes for people affected by cancer.

Mission: ICGC ARGO will analyse specimens from 100,000 cancer patients with high quality clinical data to address outstanding questions that are vital to our quest to defeat cancer. This data will made available to the research community in a rapid and responsible way.

ICGC ARGO Data Features:

- Comprehensive longitudinal annotation; clinical data describing lifestyle, comorbidity, diagnostics, response to therapy and survival
- High quality; using common quality standards for pathology and technology
- Harmonised; using central analysis and pipelines through regional data processing centres.

www.icgc-argo.org
Key questions addressed by ARGO are:

1. How do we use current treatments better?

2. How does a cancer change with time and treatment?

3. How do we translate this knowledge into improved health outcomes and more effective drug development?

4. How do we advance early detection and ultimately prevent cancer?
Member programs as of December 2020.
More details on member programs:
https://www.icgc-argo.org/page/89/project-list